INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $100,814,048 | -19.4% | 1,935,382 | -2.0% | 0.03% | -18.2% |
| Q2 2023 | $125,049,465 | +27.0% | 1,974,881 | +8.6% | 0.03% | +22.2% |
| Q1 2023 | $98,487,587 | +4.8% | 1,818,792 | +2.4% | 0.03% | -3.6% |
| Q4 2022 | $93,987,560 | +20.0% | 1,776,031 | +5.5% | 0.03% | +12.0% |
| Q3 2022 | $78,300,000 | +68.1% | 1,682,793 | +106.2% | 0.02% | +78.6% |
| Q2 2022 | $46,587,000 | +59.2% | 816,187 | +70.6% | 0.01% | +100.0% |
| Q1 2022 | $29,272,000 | +1623.9% | 478,385 | +1374.7% | 0.01% | – |
| Q4 2021 | $1,698,000 | +33.2% | 32,440 | -5.1% | 0.00% | – |
| Q3 2021 | $1,275,000 | -87.7% | 34,197 | -86.5% | 0.00% | -100.0% |
| Q2 2021 | $10,355,000 | +0.7% | 253,678 | -16.3% | 0.00% | 0.0% |
| Q1 2021 | $10,287,000 | +1344.8% | 303,174 | +1255.0% | 0.00% | – |
| Q4 2020 | $712,000 | -89.3% | 22,374 | -91.4% | 0.00% | -100.0% |
| Q3 2020 | $6,681,000 | -0.8% | 260,372 | -0.7% | 0.00% | 0.0% |
| Q2 2020 | $6,732,000 | +49.2% | 262,274 | -10.7% | 0.00% | 0.0% |
| Q1 2020 | $4,512,000 | +317.0% | 293,539 | +830.3% | 0.00% | – |
| Q4 2019 | $1,082,000 | +314.6% | 31,553 | -10.0% | 0.00% | – |
| Q3 2019 | $261,000 | -40.4% | 35,045 | +3.8% | 0.00% | – |
| Q2 2019 | $438,000 | +13.5% | 33,761 | +6.5% | 0.00% | – |
| Q1 2019 | $386,000 | +73.9% | 31,701 | +62.7% | 0.00% | – |
| Q4 2018 | $222,000 | -49.5% | 19,479 | -4.0% | 0.00% | – |
| Q3 2018 | $440,000 | +25.7% | 20,281 | +2.5% | 0.00% | – |
| Q2 2018 | $350,000 | -54.6% | 19,795 | -45.9% | 0.00% | – |
| Q1 2018 | $771,000 | -45.4% | 36,621 | -62.5% | 0.00% | -100.0% |
| Q4 2017 | $1,413,000 | +93.8% | 97,610 | +111.3% | 0.00% | – |
| Q3 2017 | $729,000 | +29.9% | 46,196 | +2.3% | 0.00% | – |
| Q2 2017 | $561,000 | +24.7% | 45,176 | +63.0% | 0.00% | – |
| Q1 2017 | $450,000 | -75.6% | 27,721 | -58.3% | 0.00% | -100.0% |
| Q1 2016 | $1,848,000 | -74.9% | 66,475 | -51.4% | 0.00% | -66.7% |
| Q4 2015 | $7,363,000 | +41.0% | 136,875 | +5.0% | 0.00% | +50.0% |
| Q3 2015 | $5,221,000 | +6955.4% | 130,389 | +5508.1% | 0.00% | – |
| Q2 2015 | $74,000 | – | 2,325 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |